Filing Flows

Filing Flows › Denali Therapeutics (DNLI) › Who owns the stock

Who owns Denali Therapeutics (DNLI) stock

272 funds reported Denali Therapeutics (DNLI) shares in their latest 13F filings, worth $4.0B in all. The largest holder is T. Rowe Price Investment Management ($416M). Last quarter 158 funds added to their stakes and 84 cut them.

Largest holders of DNLI (13F)Largest holders of DNLI (13F)T. Rowe Price Investment Manageme…$416MBlackRock$361MBaillie Gifford$308MVanguard Group$216MState Street$181MVanguard Portfolio Management LLC$167MVanguard Capital Management LLC$161MTemasek Holdings (Private)$145MFMR LLC$117MGoldman Sachs Group$107M

Largest holders (13F)

FundSharesValueChangeQuarter
T. Rowe Price Investment Management16,178,963$416Mincrease2026-06-30
BlackRock14,026,413$361Mincrease2026-06-30
Baillie Gifford11,960,230$308Mdecrease2026-06-30
Vanguard Group13,057,890$216Mincrease2025-12-31
State Street7,049,304$181Mincrease2026-06-30
Vanguard Portfolio Management LLC6,477,057$167Mincrease2026-06-30
Vanguard Capital Management LLC6,275,729$161Mincrease2026-06-30
Temasek Holdings (Private)7,012,974$145Munchanged2026-09-30
FMR LLC4,535,836$117Mdecrease2026-06-30
Goldman Sachs Group4,155,895$107Mdecrease2026-06-30
Geode Capital Management, LLC3,973,342$102Mincrease2026-06-30
Holocene Advisors, LP3,905,225$100Mincrease2026-06-30
Baker Bros. Advisors LP3,734,336$96.0Mincrease2026-06-30
UBS AM, a distinct business unit of UBS Asset Management Americas LLC3,161,972$81.3Mdecrease2026-06-30
Price T Rowe Associates3,136,149$80.7Mincrease2026-06-30

Denali Therapeutics' latest quarter

Denali Therapeutics, Q3 2026: revenue $17.8M, operating margin -713.0%, net earnings $70.1M, operating cash flow −$117M. The chart follows the revenue to costs, profit and cash.

Questions

Who owns the most DNLI stock?

By the latest 13F filings: T. Rowe Price Investment Management ($416M); BlackRock ($361M); Baillie Gifford ($308M); Vanguard Group ($216M); State Street ($181M).

What is the short interest in DNLI?

15,475,322 shares were sold short at the 2026-10-15 settlement, 0.07% of the float.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.